Skip to main content

Advertisement

SpringerLink
Log in

Hypertension up to date: SPRINT to SPYRAL

  • Review
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Hypertension is the most common chronic cardiovascular condition with increasing prevalence all over the world. Treatment of patients at risk requires a multimodal therapeutic concept to adjust blood pressure, including systematic identification of secondary causes of hypertension or pseudo-resistance, lifestyle modification, polypharmacy, and as well as accompanying risk factors and comorbidities. The present review discusses recent studies on patients with increased cardiovascular risk potentially influencing future treatment strategies. It covers blood pressure targets in patients at risk (SPRINT), novel treatment options such as angiotensin receptor neprilysin inhibitors, discusses the treatment of patients with impaired glucose tolerance, and appreciates novelties in controlling therapy-resistant hypertension by fourth-line pharmacotherapies (PATHWAY), as well as new interventional approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, Burnett R, Casey D, Coates MM, Cohen A, Delwiche K, Estep K, Frostad JJ, Kc A, Kyu HH et al (2015) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. doi:10.1016/S0140-6736(15)00128-2

    PubMed Central  Google Scholar 

  2. Drazen JM, Morrissey S, Campion EW, Jarcho JA (2015) A SPRINT to the finish. N Engl J Med. doi:10.1056/NEJMe1513991

    Google Scholar 

  3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219. doi:10.1093/eurheartj/eht151

    Article  PubMed  Google Scholar 

  4. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362(17):1575–1585. doi:10.1056/NEJMoa1001286

    Article  PubMed  Google Scholar 

  5. Lee M, Saver JL, Hong KS, Hao Q, Ovbiagele B (2012) Does achieving an intensive versus usual blood pressure level prevent stroke? Ann Neurol 71(1):133–140. doi:10.1002/ana.22496

    Article  PubMed  Google Scholar 

  6. SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM (2013) Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382(9891):507–515. doi:10.1016/S0140-6736(13)60852-1

  7. Upadhyay A, Earley A, Haynes SM, Uhlig K (2011) Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 154(8):541–548. doi:10.7326/0003-4819-154-8-201104190-00335

    Article  PubMed  Google Scholar 

  8. Benetos A, Labat C, Rossignol P, Fay R, Rolland Y, Valbusa F, Salvi P, Zamboni M, Manckoundia P, Hanon O, Gautier S et al (2015) Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study. JAMA Intern Med 175(6):989–995

    Article  PubMed  Google Scholar 

  9. Mossello E, Pieraccioli M, Nesti N (2015) Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med 175(4):578–585

    Article  PubMed  Google Scholar 

  10. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. doi:10.1056/NEJMoa1511939

    Google Scholar 

  11. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A (2016) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387:435–443

    Article  PubMed  Google Scholar 

  12. Perkovic V, Rodgers A (2015) Redefining Blood-Pressure Targets - SPRINT Starts the Marathon. N Engl J Med. doi:10.1056/NEJMe1513301

    PubMed  Google Scholar 

  13. Thomopoulos C, Parati G, Zanchetti A (2014) Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 32:2285–2295

    Article  CAS  PubMed  Google Scholar 

  14. Messerli FH, Mancia G, Conti CR et al (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerours? Ann Intern Med 144:884–893

    Article  PubMed  Google Scholar 

  15. Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, Tendera M, Tavazzi L, Bhatt DL, Steg PC et al (2016) Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet S0140-6736(16):31326–31325. doi:10.1016/S0140-6736(16)31326-5.

    Google Scholar 

  16. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH Jr, Lipkin EW, Narayan KM, Riddle MC Jr, Sood A, Goff DC Jr (2014) Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 37(6):1721–1728. doi:10.2337/dc13-2334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP (2011) Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 42(5):1489–1494. doi:10.1161/STROKEAHA.110.602615

    Article  PubMed  Google Scholar 

  18. Meyers MG, Godwin M, Daves M, Kiss A, Tobe SW, Kaczorowski J (2010) Meausurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 55:195–200

    Article  Google Scholar 

  19. Filipovsky J, Seidlerova J, Kratochvil Z, Karnosova P, Hronova M, Mayer O Jr. (2016) Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Press. doi:10.3109/08037051.2015.1134086

    PubMed  Google Scholar 

  20. Lonn EN, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Yusuf S (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374:2009–2020

    Article  CAS  PubMed  Google Scholar 

  21. Packer M (1995) Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 16(Suppl F):4–6. doi:10.1093/eurheartj/16.suppl_F.4.

    Article  CAS  PubMed  Google Scholar 

  22. Ruilope LM, Dukat A, Böhm M, Lacourciere Y, Gong J, Lefkowitz MP (2010) Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. The Lancet 375(9722):1255–1266. doi:10.1016/S0140-6736(09)61966-8

    Article  CAS  Google Scholar 

  23. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT (1992) Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 10(7):607–613

    Article  CAS  PubMed  Google Scholar 

  24. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E (2004) Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens 17(2):103–111. doi:10.1016/j.amjhyper.2003.09.014

    Article  CAS  PubMed  Google Scholar 

  25. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H, Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. doi:10.1056/NEJMoa1409077

    Article  PubMed  Google Scholar 

  26. Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD (2014) Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail 16(6):671–677. doi:10.1002/ejhf.76

    Article  CAS  PubMed  Google Scholar 

  27. Catala-Lopez F, Macias Saint-Gerons D, de la Fuente Honrubia C, Martin-Serrano G (2014) Risks of dual blockade of the renin-angiotensin system compared with monotherapy: a systematic review and cumulative meta-analysis of randomized trials and observational studies. Rev Esp Salud Publica 88(1):37–65.

    Article  PubMed  Google Scholar 

  28. Gaziano TA, Fonarow GC, Claggett B et al (2016) Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol 1(6):666–672

    Article  PubMed  Google Scholar 

  29. McMurray JJ, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM, ATMOSPHERE Committees Investigators (2016) Aliskiren, enalapril or aliskiren and enalapril in heart failure. N Engl J Med 374(16):1521–1532

    Article  CAS  PubMed  Google Scholar 

  30. Williams B, Cockcroft JR, Kario K, Zappe DH, Cardenas P, Hester A, Brunel P, Zhang J (2014) Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open 4(2):e004254. doi:10.1136/bmjopen-2013-004254

    Article  PubMed  PubMed Central  Google Scholar 

  31. Williams B, Cockcroft JR, Kario K, Zappe DH, Wang Q, Guo W (2015) Principal results of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin Receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) Study. ESC Congress 2015; (London) oral presentation, 31 Aug 2015

  32. Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557):201–207. doi:10.1016/S0140-6736(07)60108-1

    Article  CAS  PubMed  Google Scholar 

  33. Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM, British Hypertension Society’s P, Treatment of Hypertension with Algorithm-based Therapy Studies G (2015) Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. doi:10.1016/S2213-8587(15)00377-0

    Google Scholar 

  34. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J et al (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2224–2260. doi:10.1016/S0140-6736(12)61766-8

    Article  PubMed  PubMed Central  Google Scholar 

  35. Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I, Brown MJ (2015) Prevention and treatment of hypertension with algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open 5(8):e008951. doi:10.1136/bmjopen-2015-008951.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, Vaclavik T, Husar R, Kocianova E, Taborsky M (2011) Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57(6):1069–1075. doi:10.1161/HYPERTENSIONAHA.111.169961

    Article  CAS  PubMed  Google Scholar 

  37. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA (2013) Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 31(10):2094–2102. doi:10.1097/HJH.0b013e3283638b1a

    Article  CAS  PubMed  Google Scholar 

  38. DiBona GF (2005) Physiology in perspective: the Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 289(3):R633–R641. doi:10.1152/ajpregu.00258.2005

    Article  CAS  PubMed  Google Scholar 

  39. Ewen S, Ukena C, Böhm M, Mahfoud F (2013) Percutaneous renal denervation: new treatment option for resistant hypertension and more? Heart 99(15):1129–1134. doi:10.1136/heartjnl-2012-301725

    Article  CAS  PubMed  Google Scholar 

  40. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370(15):1393–1401. doi:10.1056/NEJMoa1402670

    Article  CAS  PubMed  Google Scholar 

  41. Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G, Investigators GSR (2015) First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 65(4):766–774. doi:10.1161/HYPERTENSIONAHA.114.05010

    Article  PubMed  Google Scholar 

  42. Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D, Kindermann I, Ukena C, Burnier M, Wagenpfeil S, Maurer HH, Böhm M, Mahfoud F (2015) Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol 104(12):1097–1105

    Article  CAS  PubMed  Google Scholar 

  43. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S et al (2015) Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 36(4):219–227. doi:10.1093/eurheartj/ehu441

    Article  PubMed  Google Scholar 

  44. Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P, Bednar F, Zelinka T, Holaj R, Strauch B, Somloova Z, Taborsky M, Vaclavik J, Kocianova E, Branny M et al (2015) Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 65(2):407–413. doi:10.1161/HYPERTENSIONAHA.114.04019

    Article  CAS  PubMed  Google Scholar 

  45. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand P-Y, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin P-F et al (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. The Lancet 385:1957–1965. doi:10.1016/s0140-6736(14)61942-5

    Article  Google Scholar 

  46. Pöss J, Ewen S, Schmieder RE, Muhler S, Vonend O, Ott C, Linz D, Geisel J, Rump LC, Schlaich M, Böhm M, Mahfoud F (2015) Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clin Res Cardiol 104(8):672–678

    Article  PubMed  Google Scholar 

  47. Kandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Pocock S, Townsend R, Weber MA, Böhm M (2015) The SPYRAL HTN global clinical trial program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J. doi:10.1016/j.ahj.2015.08.021

    PubMed  Google Scholar 

  48. Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, Linz D, Davies J, Kandzari DE, Whitbourn R, Bohm M, Melder RJ (2015) Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol 66(16):1766–1775. doi:10.1016/j.jacc.2015.08.018

    Article  PubMed  Google Scholar 

  49. Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE et al (2015) Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 36(33):2219–2227. doi:10.1093/eurheartj/ehv192

    Article  PubMed  Google Scholar 

  50. Spiering W, Van der Heyden J, Kroon AA, van der Meiracker AH, Devireddy C, Foster MT, Ghali MG, Mendelsohn FO, Reuter H, Bates MC et al (2016) Controlling and lowering blood pressure with the MobiusHD device: first-in-man interim results (CALM-FIM-Study). J Hypertens 2016(Suppl 2):e105. doi:10.1097/01.hjh.0000491608.58838.2e

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str., IMED, 66421, Homburg (Saar), Germany

    Saarraaken Kulenthiran, Sebastian Ewen, Michael Böhm & Felix Mahfoud

Authors
  1. Saarraaken Kulenthiran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sebastian Ewen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Felix Mahfoud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saarraaken Kulenthiran.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kulenthiran, S., Ewen, S., Böhm, M. et al. Hypertension up to date: SPRINT to SPYRAL. Clin Res Cardiol 106, 475–484 (2017). https://doi.org/10.1007/s00392-017-1095-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-017-1095-0

Keywords

Search

Navigation